NCT06901856Not yet recruiting
Endoscopic Resection for Small Rectal Neuroendocrine Tumors
Modified Cap-assisted Endoscopic Mucosal Resection and Modified Endoscopic Mucosal Resection with a Ligation Device for Small Rectal Neuroendocrine Tumors Less Than 1 Cm: a Muticenter Randomized Noninferiority Trial
Source: ClinicalTrials.gov · Last updated 30 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
According to clinical practice and relevant retrospective research data, both modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic mucosal resection with a ligation device(ESMR-L) were reported to be effective for the treatment of small rectal neuroendocrine tumors (NETs) . However, there is a lack of multicenter prospective studies to evaluate the advantages and disadvantages of mEMR-C and mEMR-L. mEMR-C is the modified ESMR-L without submucosal injection.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 24 Mar 2025
- Start date
- Mar 2025
- Primary completion date
- Dec 2025
- Lead sponsor
- Guangdong Provincial People's Hospital
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT06901856
What you commit to
- Study type: Interventional
- Planned participants: 120
- From Mar 2025 to the primary completion date, Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received resection of rectal neuroendocrine tumor by other surgical procedures;
Other illness
- Complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation;
- Vulnerable groups such as pregnant women or patients with mental disorders;
Other
- Unable to tolerate mEMR-L or mEMR-C as assessed by the research team of each center;
- Rectal NET with lymph node metastasis or distant metastasis;
- Multiple rectal neuroendocrine tumors;
- Poor compliance, unable to cooperate with treatment.
Who the study is looking for
- Age from 18 to 80 years;
- With a high suspicion or evidence of rectal NET assessed using EUS or colonoscopy;
- With tumor size ≤10 mm assessed by colonoscopy;
- Plan to receive mEMR-C or mEMR-L treatment and provide written informed consent;
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.